PIK3CA MUTATION
Clinical trials for PIK3CA MUTATION explained in plain language.
Never miss a new study
Get alerted when new PIK3CA MUTATION trials appear
Sign up with your email to follow new studies for PIK3CA MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to shrink overgrown tissue in rare genetic disorder
Disease control Recruiting nowThis study tests a new drug, RLY-2608, in adults and children with rare conditions that cause abnormal overgrowth of body parts (like limbs or organs) due to a PIK3CA gene mutation. The drug targets only the mutated protein to try to reduce the size of overgrown tissue and improv…
Matched conditions: PIK3CA MUTATION
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 04:05 UTC
-
New drug targets tough cancers in early human trial
Disease control Recruiting nowThis early-stage study tests a new drug, RLY-2608, designed to target a specific genetic mutation (PIK3CA) found in some advanced solid tumors and breast cancers. The trial will enroll about 930 adults whose cancer has not responded to other treatments. Researchers aim to find th…
Matched conditions: PIK3CA MUTATION
Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New hope for advanced breast cancer: targeted drug combo tested in phase 3 trial
Disease control Recruiting nowThis study tests whether a new drug, RLY-2608, combined with fulvestrant works better than another drug combo (capivasertib + fulvestrant) for people with a specific genetic mutation (PIK3CA) in advanced hormone-receptor-positive, HER2-negative breast cancer. About 540 adults who…
Matched conditions: PIK3CA MUTATION
Phase: PHASE3 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New pill targets Hard-to-Treat cancers with PIK3CA mutation
Disease control Recruiting nowThis early-phase study tests an experimental oral drug, RGT-490, in adults with advanced solid tumors (including breast, ovarian, and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to check safety, find the right dose, and see if the dr…
Matched conditions: PIK3CA MUTATION
Phase: PHASE1 • Sponsor: Regor Pharmaceuticals Inc. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC